Ibrutinib (Imbruvica) and the BTK Inhibitor Race

Ibrutinib, marketed as Imbruvica, was the first-in-class Bruton’s tyrosine kinase (BTK) inhibitor. It changed treatment for chronic lymphocytic leukemia (CLL) and several B-cell lymphomas by replacing chemotherapy-based regimens with an oral, continuous therapy.

Mechanism at a glance

Ibrutinib irreversibly binds a cysteine residue in BTK, a kinase that drives B-cell receptor signaling and survival. It is taken orally and continuously. Atrial fibrillation, hypertension and bleeding are the best-known adverse effects, which is why tolerability became the main point of differentiation for later inhibitors.

A class that kept evolving

Once ibrutinib proved the target, others followed with the goal of better selectivity and tolerability. Second-generation covalent inhibitors, including acalabrutinib and zanubrutinib, were developed to reduce off-target effects. Pirtobrutinib, a non-covalent inhibitor, was first approved for patients who progressed on covalent agents and, in October 2026, received US approval in previously untreated CLL/SLL, which puts it in direct contact with first-line ibrutinib. BTK degraders are in clinical development.

Key competitive questions

• Tolerability: how do cardiovascular events, bleeding and other adverse effects compare across inhibitors?
• Duration: will fixed-duration combinations, such as a BTK inhibitor with venetoclax, displace continuous therapy for some patients?
• Resistance: how do BTK mutations shape later-line choices?
• Beyond CLL: how will mantle cell lymphoma, Waldenström macroglobulinemia and other indications shift the class?

What to watch

Head-to-head trials between BTK inhibitors, data on measurable residual disease with time-limited regimens, and the emergence of BTK degraders and bispecific antibodies in earlier lines. See also our venetoclax landscape, since the two drugs are increasingly studied together.

Recent developments

Updated October 8, 2026. Items are drawn from company announcements, regulators and trade press; links go to the sources.

• Oct 2, 2026: FDA approved Jaypirca (pirtobrutinib) for previously untreated CLL/SLL without a 17p deletion, based on BRUIN CLL-313 vs bendamustine-rituximab (n=282): PFS HR 0.20 and response rate 94% vs 81%. (CURE)
• Jun 26, 2026: The EMA’s CHMP issued a positive opinion for Jaypirca across all CLL lines. As of this update, I could not confirm that the European Commission has acted on it. (ChemXplore)
• Feb 2026: FDA approved acalabrutinib (Calquence) plus venetoclax, a fixed-duration all-oral regimen, for previously untreated CLL/SLL (AMPLIFY): 36-month PFS of 76.5% vs 66.5% against chemoimmunotherapy. The comparator was FCR or BR, not ibrutinib. (Targeted Oncology)
• Jan 2026: Under Medicare drug price negotiation, the negotiated Part D price of Imbruvica took effect at $9,319 per 30-day supply, 38% below the 2023 list price. ASCO Post reports that generic entry is delayed until 2032 under a settlement; that date comes from a single source. (ASCO Post)
• Dec 2025: At ASH, BRUIN CLL-314 showed pirtobrutinib noninferior to ibrutinib on response rate in BTK-inhibitor-naive CLL/SLL (87.0% vs 78.5%). Atrial fibrillation or flutter occurred in 2.4% vs 13.5%. Reported enrollment was 662 patients in one source and 650 in others. (Oncology Nursing News)
• Dec 3, 2025: FDA granted traditional approval to Jaypirca for relapsed or refractory CLL/SLL after a covalent BTK inhibitor (BRUIN CLL-321), converting its earlier accelerated approval. (CURE)
• Dec 2025: Long-term ALPINE follow-up for zanubrutinib (up to six years) was presented at ASH, with median PFS of 52.5 months for the zanubrutinib arm. (AJMC)
• Jul 23, 2025: The European Commission approved ibrutinib with R-CHOP/R-DHAP followed by ibrutinib monotherapy for previously untreated, transplant-eligible mantle cell lymphoma (TRIANGLE), per J&J. (J&J)

Upcoming catalysts

• Pending: a European Commission decision on Jaypirca across CLL lines, following the June 2026 CHMP opinion (status unconfirmed).
• Second half of 2026: BeOne has said it anticipates a potential accelerated-approval submission for its BTK degrader BGB-16673 in relapsed or refractory CLL (company guidance; I could not confirm it has been filed).

Bottom line

Ibrutinib created the category, but selectivity, convenience and finite-duration regimens now define the contest. Clear comparison tables of tolerability and outcomes are among the most useful tools a CI team can maintain in this space.

Want this kind of analysis for the cancer areas you compete in? Request information and we will share sample deliverables.

This article is for informational and competitive-intelligence purposes only and is not medical advice. Approvals, labels and trial results change; verify details against current prescribing information and primary sources.